Tag: Mersana Therapeutics
Mersana Presents Interim Phase 1 Data for XMT-1536 at the 2019...
Mersana Therapeutics, a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates or ADCs targeting cancers in areas of high...
Mersana Therapeutics Focuses its Resources on Advancing XMT-1536, its First-in-Class ADC...
Mersana Therapeutics, a clinical-stage biopharmaceutical company developing a pipeline of antibody-drug conjugates or ADCs designed to target cancers in areas of high unmet need,...
Preclinical Data Supports the Development of XMT-1536 in a Broad Population...
Update data from preclinical studies with XMT-1536, an antibody-drug conjugates or ADC being developed by Mersana Therapeutics targeting NaPi2b, were presented in a poster...
AACR 2017: New Preclinical Data to be Presented on Mersana’s XMT-1522
Mersana Therapeutics earlier today announced that it will present data on its lead preclinical immunoconjugate, XMT-1522, at the American Association of Cancer Research (AACR)...
Mersana’s XMT-1536 Demonstrates Anti-tumor Activity in Lung Cancer Patient-Derived Xenograft Studies
Encouraging data from preclinical studies presented at the 2016 IASLC 17th World Conference on Lung Cancer, in Vienna, Austria, suggests that Mersana Therapeutics' immunoconjugate XMT-1536...
U.S. FDA Accepts Investigational New Drug Application for Mersana’s Lead Antibody-Drug...
The U.S. Food and Drug Administration (FDA) cleared Mersana Therapeutics’ Investigational New Drug (IND) application to begin Phase I clinical trials for its lead...
Best ADC Platform Technology Awarded to Mersana Therapeutics
This week, during the 7th World ADC Conference in San Diengo, Mersana Therapeutics, a biotechnology company focused on discovering and developing a pipeline of...
XMT-1536 Demonstrates Anti-Cancer Activity in Patients with NaPi2b-expressing Tumors
Preclinical data for Mersana Therapeutics' new immunoconjugate product candidate, XMT-1536, demonstrated significant anti-cancer activity in non-small cell lung cancer (NSCLC) and ovarian cancer tumor models. The...
Mersana and Recepta Sign Agreement for Novel Antibody
Cambridge based Mersana Therapeutics and Recepta Biopharma, a clinical stage Brazilian biotechnology company, have entered into an exclusive license agreement in which Mersana will...
XMT-1522 Demonstrates Potent Activity in Low HER2-Expressing Tumor Models
Preclinical data for XMT-1522, a novel HER2-targeting therapy based on Mersana Therapeutics' Dolaflexin platform, the company's most advanced Fleximer® proprietary immunoconjugate technology, demonstrates significant anti-cancer activity...
DOWNLOAD
